Cerenome (PSTV) Total Debt (2010 - 2026)

Plus Therapeutics (PSTV) posted quarterly Total Debt of $667000.0 for Q1 2026, down 11.07% quarter-over-quarter from $750000.0 in Q4 2025.

Cerenome (PSTV) Total Debt (2010 - 2026) Analysis & Trends

Plus Therapeutics (PSTV) has reported Total Debt for 17 consecutive years, with $667000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Total Debt changed N/A year-over-year to $667000.0; the TTM figure through Mar 2026 stood at $667000.0 (changed N/A YoY), while the FY2025 annual figure was $750000.0, down 77.22% from the prior year.
Total Debt eased to $667000.0 in Q1 2026 per PSTV's latest filing, from $750000.0 in the prior quarter.
Across five years, Total Debt topped out at $6.3 million in Q1 2022 and bottomed at $667000.0 in Q1 2026.
Historically, Total Debt has averaged $4.0 million across 5 years, with a median of $4.2 million in 2023.
Annual changes were most pronounced in 2022 — Total Debt dropped 2.47% — and 2025, when it slumped 77.22%.
Plus Therapeutics' Total Debt stood at $5.4 million in 2022, then declined by 26.29% to $4.0 million in 2023, then fell by 17.2% to $3.3 million in 2024, then plunged by 77.22% to $750000.0 in 2025, then dropped by 11.07% to $667000.0 in 2026.
Business Quant data shows PSTV's Total Debt at $667000.0 in Q1 2026, $750000.0 in Q4 2025, and $3.3 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	Cerenome	28.07 Mn	19.48 Mn	-	-

Download Data